Diagnostic Efficiency of Determining CXCR1, CXCR2 and Hyaluronic Acid in Blood of Patients with Non-Small Cell Lung Cancer

IF 0.6 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry Pub Date : 2022-02-14 DOI:10.1134/S1990750822010073

D. I. Murashka, A. D. Tahanovich, M. M. Kauhanka, V. I. Prokhorova, O. V. Gotko

{"title":"Diagnostic Efficiency of Determining CXCR1, CXCR2 and Hyaluronic Acid in Blood of Patients with Non-Small Cell Lung Cancer","authors":"D. I. Murashka, A. D. Tahanovich, M. M. Kauhanka, V. I. Prokhorova, O. V. Gotko","doi":"10.1134/S1990750822010073","DOIUrl":null,"url":null,"abstract":"<div><div><h3>\n <b>Abstract</b>—</h3><p>Non-small cell lung cancer (NSCLC) accounts for most cases of lung cancer. Histologically, it is subdivided into two histological subtypes: adenocarcinoma (AC) and squamous cell carcinoma (SCC). The five-year survival rate of patients with stage I NSCLC is two times higher than in patients with stage II and more than five times higher than in stage III−IV lung cancer patients. Currently, there are no informative blood biomarkers to diagnose early stages of NSCLC. The aim of this study was to evaluate complex determination of hyaluronic acid (HA), lymphocyte CXCR2 and granulocyte CXCR1 levels in the blood of patients with AC and SCC. Blood samples from 107 patients with SCC, 90 patients with AC, and 40 healthy people were used in this study. Concentration of HA in blood serum was determined by enzyme linked immunoassay. The level of CXCR2 and CXCR1 was determined by flow cytometry. Diagnostic parameters were determined by constructing mathematical models in the form of regression equations using the method of stepwise inclusion of predictors and subsequent ROC-analysis. Results of the study indicate that MFI CXCR1 in granulocytes, the proportion of lymphocytes expressing CXCR2 and concentration of HA in blood serum in stage I AC and SCC are significantly higher than in healthy people. The level of these indicators significantly increases at stage II of the disease compared to stage I and demonstrates further growth at its later stages. Based on obtained results, regression equations were created. These included: (i) MFI CXCR1 in granulocytes, the proportion of lymphocytes supplied with CXCR2 and the HA serum concentration in to detect stages I−II SCC (diagnostic sensitivity 95.7%, specificity 93.7%, threshold value 0.59) and stages III−IV SCC (diagnostic sensitivity 93.1%, specificity 93.3%, threshold value 0.64); (ii) the proportion of lymphocytes supplied with CXCR2, MFI CXCR1 in granulocytes and CYFRA 21-1 blood level, for detection of I−II stages of AC (sensitivity 91.3%, specificity 94.7%, threshold value 0.61); (iii) the proportion of lymphocytes expressing CXCR2 and CYFRA 21-1 blood level, for detection of AC stages III–IV (sensitivity 94.6%, specificity 91.3%, threshold value 0.15); (IV) the proportion of lymphocytes expressing CXCR2 and serum HA level to differentiate stage II SCC from stage I (sensitivity 94.4%, specificity 87.5%, threshold value 0.44) and II stage AC from stage I (sensitivity 88.5%, specificity 91.2%, threshold value 0.46).</p></div></div>","PeriodicalId":485,"journal":{"name":"Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry","volume":"16 1","pages":"45 - 53"},"PeriodicalIF":0.6000,"publicationDate":"2022-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry","FirstCategoryId":"2","ListUrlMain":"https://link.springer.com/article/10.1134/S1990750822010073","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract—

Non-small cell lung cancer (NSCLC) accounts for most cases of lung cancer. Histologically, it is subdivided into two histological subtypes: adenocarcinoma (AC) and squamous cell carcinoma (SCC). The five-year survival rate of patients with stage I NSCLC is two times higher than in patients with stage II and more than five times higher than in stage III−IV lung cancer patients. Currently, there are no informative blood biomarkers to diagnose early stages of NSCLC. The aim of this study was to evaluate complex determination of hyaluronic acid (HA), lymphocyte CXCR2 and granulocyte CXCR1 levels in the blood of patients with AC and SCC. Blood samples from 107 patients with SCC, 90 patients with AC, and 40 healthy people were used in this study. Concentration of HA in blood serum was determined by enzyme linked immunoassay. The level of CXCR2 and CXCR1 was determined by flow cytometry. Diagnostic parameters were determined by constructing mathematical models in the form of regression equations using the method of stepwise inclusion of predictors and subsequent ROC-analysis. Results of the study indicate that MFI CXCR1 in granulocytes, the proportion of lymphocytes expressing CXCR2 and concentration of HA in blood serum in stage I AC and SCC are significantly higher than in healthy people. The level of these indicators significantly increases at stage II of the disease compared to stage I and demonstrates further growth at its later stages. Based on obtained results, regression equations were created. These included: (i) MFI CXCR1 in granulocytes, the proportion of lymphocytes supplied with CXCR2 and the HA serum concentration in to detect stages I−II SCC (diagnostic sensitivity 95.7%, specificity 93.7%, threshold value 0.59) and stages III−IV SCC (diagnostic sensitivity 93.1%, specificity 93.3%, threshold value 0.64); (ii) the proportion of lymphocytes supplied with CXCR2, MFI CXCR1 in granulocytes and CYFRA 21-1 blood level, for detection of I−II stages of AC (sensitivity 91.3%, specificity 94.7%, threshold value 0.61); (iii) the proportion of lymphocytes expressing CXCR2 and CYFRA 21-1 blood level, for detection of AC stages III–IV (sensitivity 94.6%, specificity 91.3%, threshold value 0.15); (IV) the proportion of lymphocytes expressing CXCR2 and serum HA level to differentiate stage II SCC from stage I (sensitivity 94.4%, specificity 87.5%, threshold value 0.44) and II stage AC from stage I (sensitivity 88.5%, specificity 91.2%, threshold value 0.46).

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

非小细胞肺癌患者血中CXCR1、CXCR2及透明质酸检测的诊断价值

非小细胞肺癌(NSCLC)占肺癌的大多数病例。在组织学上，它被细分为两个组织学亚型:腺癌(AC)和鳞状细胞癌(SCC)。I期NSCLC患者的5年生存率是II期患者的2倍，是III - IV期肺癌患者的5倍以上。目前，还没有信息性的血液生物标志物来诊断早期非小细胞肺癌。本研究的目的是评估AC和SCC患者血液中透明质酸(HA)、淋巴细胞CXCR2和粒细胞CXCR1水平的复杂测定。本研究使用了107例SCC患者、90例AC患者和40名健康人的血液样本。采用酶联免疫分析法测定血清HA浓度。流式细胞术检测CXCR2和CXCR1的表达水平。采用逐步纳入预测因子和roc分析的方法，以回归方程的形式建立数学模型，确定诊断参数。本研究结果表明，I期AC和SCC患者粒细胞中MFI CXCR1、表达CXCR2的淋巴细胞比例和血清HA浓度均显著高于健康人。与第一阶段相比，这些指标的水平在疾病的第二阶段显著增加，并在其后期进一步增长。根据得到的结果，建立了回归方程。这些包括:(i)粒细胞中MFI CXCR1, CXCR2提供淋巴细胞的比例和HA血清浓度用于检测i - II期SCC(诊断敏感性95.7%，特异性93.7%，阈值0.59)和III - IV期SCC(诊断敏感性93.1%，特异性93.3%，阈值0.64);(ii)用于检测I - ii期AC的CXCR2、MFI CXCR1供体淋巴细胞比例和CYFRA 21-1血水平(敏感性91.3%，特异性94.7%，阈值0.61);(iii)血中表达CXCR2和CYFRA 21-1的淋巴细胞比例，用于AC iii - iv期的检测(敏感性94.6%，特异性91.3%，阈值0.15);(IV)表达CXCR2的淋巴细胞比例和血清HA水平对II期SCC与I期(敏感性94.4%，特异性87.5%，阈值0.44)和II期AC与I期(敏感性88.5%，特异性91.2%，阈值0.46)的鉴别。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry BIOCHEMISTRY & MOLECULAR BIOLOGY-

CiteScore

1.10

自引率

0.00%

发文量

期刊介绍： Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry covers all major aspects of biomedical chemistry and related areas, including proteomics and molecular biology of (patho)physiological processes, biochemistry, neurochemistry, immunochemistry and clinical chemistry, bioinformatics, gene therapy, drug design and delivery, biochemical pharmacology, introduction and advertisement of new (biochemical) methods into experimental and clinical medicine. The journal also publishes review articles. All issues of the journal usually contain solicited reviews.